Price
$184.56+55.29%Social Signal Score
Analyst Ratings
12 analystsRevenue
$560.44M+485.69%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vivek Jain
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 13,000
- Beta
- 0.76
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.64
Financials
Revenue
$560.44M+485.7%Net Income
$26.85M+182.2%EBITDA
$103.88M+243.9%Free Cash Flow
$83.40M+564.0%EPS (diluted)
$1.07+98.1%Shares Outstanding (diluted)
25.14M+43.2%Operating Expenses
$176.16MCash & Debt
$301.78MReturn of Capital
$0.00Revenue by Segment (annual)
$105.32MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.23B | $732.0K | $0.03 |
| 2024 | $2.38B | $-117.69M | $-4.83 |
| 2023 | $2.26B | $-29.66M | $-1.23 |
| 2022 | $2.28B | $-74.29M | $-3.11 |
| 2021 | $1.32B | $103.14M | $4.86 |
| 2020 | $1.27B | $86.87M | $4.16 |
| 2019 | $1.27B | $101.03M | $4.90 |
| 2018 | $1.40B | $28.79M | $1.33 |
| 2017 | $1.29B | $68.64M | $3.50 |
| 2016 | $379.37M | $63.08M | $3.90 |
| 2015 | $341.67M | $44.98M | $2.84 |
| 2014 | $309.26M | $26.34M | $1.72 |
| 2013 | $313.72M | $40.42M | $2.75 |
| 2012 | $316.87M | $41.28M | $2.90 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ICUI's reported EPS growth of -29.7% a year over 13 years. Historical EPS growth of -30% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.01
- Implied price
- $0.24
- Return from $179.27
- -73.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.12 — -99.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -25.0% | -78.4% | -77.4% | -76.6% | -75.8% | -75.2% |
| -20.0% | -76.9% | -75.9% | -75.0% | -74.2% | -73.5% |
| -15.0% | -75.5% | -74.4% | -73.4% | -72.6% | -71.9% |
| -10.0% | -74.1% | -72.9% | -71.9% | -71.0% | -70.2% |
| -5.0% | -72.6% | -71.4% | -70.3% | -69.4% | -68.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+0.00%Social Signal Score
Mentions (9)
- Newszacks.com·5d ago·Positive
3 Reasons Growth Investors Will Love ICU Medical (ICUI) ICU Medical (ICUI) could produce exceptional returns because of its solid growth attributes.
View source ↗ - News (Marketaux)seekingalpha.com·16d ago·Neutral
Icu Medical signals 2026 results toward high end of $415M-$435M EBITDA and $8.60-$9 EPS range as logistics consolidation normalizes (NASDAQ:ICUI) Icu Medical signals 2026 results toward high end of $415M-$435M EBITDA and $8.60-$9 EPS range as logistics consolidation normalizes (NASDAQ:ICUI)
View source ↗ - Newszacks.com·17d ago·Neutral
ICU Medical (ICUI) Reports Q3 Earnings: What Key Metrics Have to Say The headline numbers for ICU Medical (ICUI) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
ICU Medical, Inc. (ICUI) Q3 2026 Earnings Call Transcript ICU Medical, Inc. (ICUI) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·44d ago·Neutral
3 Medical Product Stocks Positioned to Ride on the Industry Tailwinds Here, we highlight three medical product stocks, ICUI, NEOG and TRLV, which are well positioned to benefit from industry tailwinds and could be worth adding to investors' portfolios.
View source ↗ - Newsgurufocus.com·61d ago·Neutral
A Look at ICU Medical Inc (ICUI) After 3.7% Gain -- GF Value $121.40 vs Price $160.98 On September 22, 2026, ICU Medical Inc (ICUI) shares rose 3.7%, bringing the current price to $160.98. The stock has fluctuated within a 52-week range of $112.5
View source ↗ - Newsfool.com·67d ago·Negative
ICU Medical CFO Brian Bonnell Sells 9,307 Shares Bonnell retains 62,443 direct shares.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
ICU Medical, Inc. (ICUI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ICU Medical, Inc. (ICUI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (Marketaux)insidermonkey.com·105d ago·Negative
Q2 Earnings Blowouts: 37 Stock That Beat Expectations ICU Medical, Inc</[+368 characters]
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $2.15 per share
Typical surprise +24.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$2.44 vs $2.14beat
- Thu, Aug 6$2.37 vs $1.91beat
- Thu, May 7$1.97 vs $1.78beat
- Thu, Feb 19$1.91 vs $1.68beat
- Thu, Nov 6$2.03 vs $1.43beat
- Thu, Aug 7$2.10 vs $1.44beat
Estimates and results for ICUI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ICUI officers and directors.
- Bought
- —
- Sold
- $7.8m
0 trades
17 trades
- Finney Elisha Wsold
- Sanzone Virginia Ruthsold
- Sanzone Virginia Ruthsold
- Sanzone Virginia Ruthsold
- Sanzone Virginia Ruthsold
- Bonnell Brian Michaelsold
- Bonnell Brian Michaelsold
- Bonnell Brian Michaelsold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2025 (34d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 6, 2024 (6d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Mar 18, 2022 (32d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 11, 2021 (19d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 7, 2021 (17d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 14, 2020 (20d later)Buy$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 14, 2020 (21d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 14, 2020 (19d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 16, 2020 (16d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Sep 16, 2019 (52d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Sep 11, 2019 (27d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Aug 19, 2019 (20d later)Sell$1,001 - $15,000
- Thomas Roland Tillissenate · NC · disclosed Feb 26, 2015 (13d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
